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There is a complex relationship between tuberculosis and nutri­
tion. [1] The immunodeficiency caused by undernutrition increases 
the risk of acquiring tuberculosis.[2] Alternatively, tuberculosis may 
cause undernutrition through increased metabolic demands and 
decreased appetite. The resulting nutritional deficiencies may worsen 
the disease or delay recovery by depressing immune function.[3,4] A 
key guiding principle of the World Health Organization guidelines on 
nutritional care and support for patients with tuberculosis[5] is that ‘an 
adequate diet, containing all essential macro­ and micronutrients, is 
necessary for the well­being and health of all people, including those 
with TB infection or TB disease’. However, owing to limited available 
evidence there is still no evidence­based nutritional guidance specific 
to adults and children who are being treated for active tuberculosis. 
We summarise the evidence from an updated Cochrane review 
assessing the effects of oral nutritional supplements on all­cause 
death and cure at 6 and 12 months in patients receiving treatment for 
active tuberculosis.[1]
Methods
The review authors conducted a comprehensive search of eight 
databases up to February 2016, without language or date restrictions. 
All randomised controlled trials comparing any oral nutritional 
supplement, given for at least 4 weeks, with no nutritional inter­
vention, placebo or dietary advice only to patients receiving 
treatment for active tuberculosis were included. The review authors 
followed standard Cochrane methods for independent screening 
and eligibility assessment, data extraction, risk of bias assessment 
and data analysis. The quality of the evidence was assessed using 
the Grading of Recommendation Assessment, Development and 
Evaluation (GRADE) approach.[1]
Results
Of the 35 eligible trials (N=8 283 participants), four were conducted 
in children (n=739) and 11 specifically presented disaggregated out­
come data for HIV­positive and HIV­negative participants. Most of 
the trials were conducted in Africa and Asia.
Macronutrient supplementation
Seven trials investigated the effect of providing free food or high­
energy nutritional supplements. The trials were too small to reliably 
demonstrate or exclude clinically important benefits on mortality 
(risk ratio (RR) 0.34, 95% confidence interval (CI) 0.10 ­ 1.20; four 
trials, 567 participants, very low­quality evidence), cure (RR 0.91, 
95% CI 0.59 ­ 1.41; one trial, 102 participants, very low­quality 
evidence), or treatment completion (data not pooled; two trials, 
365 participants, very low­quality evidence). Providing free food 
or high­energy nutritional supplements probably produces modest 
weight gain during treatment for active tuberculosis, although this 
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was not consistent across all included trials (data not pooled; five 
trials, 883 participants, mean weight gain 0.78 ­ 2.6 kg, moderate­
quality evidence). There is some evidence that quality of life may be 
improved, but the trials were too small to have much confidence in 
the result (data not pooled; two trials, 134 participants, low­quality 
evidence) (Table 1).[1]
Multi-micronutrient supplementation
Six trials assessed multi­micronutrient supplementation in doses up 
to 10 times the recommended dietary allowance (RDA).[6] Routine 
multi­micronutrient supplementation may have little or no effect on 
mortality in HIV­negative people with tuberculosis (RR 0.86, 95% 
CI  0.46 ­ 1.6; four trials, 1 219 participants, low­quality evidence), 
or HIV­positive people not taking antiretroviral therapy (RR 0.92, 
95% CI 0.69 ­ 1.23; three trials, 1 429 participants, moderate­quality 
evidence). There is insufficient evidence to know whether multi­
micronutrient supplementation improves cure (no trials), treatment 
completion (RR 0.99, 95% CI 0.95 ­ 1.04; one trial, 302 participants, 
very low­quality evidence), or the proportion of people who remain 
sputum­positive during the first 8 weeks of antituberculosis treatment 
(RR 0.92, 95% CI 0.63 ­ 1.35; two trials, 1 020 participants, very low­
quality evidence). Furthermore, multi­micronutrient supplemen­
tation may have little or no effect on weight gain during treatment 
(data not pooled; five trials, 2 940 participants, low­quality evidence), 
and no studies have assessed the effect on quality of life. The summary 
of findings for multi­micronutrient supplementation is available for the 
outcomes death, cure rate, treatment completion, remaining sputum­
positive (4 weeks), weight gain and quality of life.[1]
Single- or dual-micronutrient supplementation
Eighteen trials assessed single­ or dual­micronutrient supple­
mentation. Low vitamin A levels are common in tuberculosis, and 
plasma levels of vitamin A appear to increase following initiation 
of antituberculosis treatment regardless of supplementation. There 
is no evidence that vitamin A supplementation in doses up to three 
times the RDA has a beneficial effect on tuberculosis treatment 
outcomes (i.e. death (RR 0.97, 95% CI 0.84 ­ 1.12; eight trials, 
3 308 participants), sputum smear­ or culture­positive after 4 
weeks (RR 0.70, 95% CI 0.33 ­ 1.48; one trial, 148 participants)) or 
nutritional recovery (body mass index: RR 0.3, 95% CI –0.44 ­ 1.04; 
one trial, 148 participants). In contrast, supplementation probably 
improves plasma levels of zinc, vitamin D, vitamin E and selenium, 
but this has not been shown to have clinically important benefits. 
Of note, despite multiple studies of vitamin D supplementation 
in different doses, statistically significant benefits on sputum 
conversion have not been demonstrated (number of participants 
who were sputum smear­ or culture­positive after 4 weeks: RR 0.87, 
95% CI 0.74 ­ 1.03; five trials, 929 participants).[1]
Table 1. Summary of findings: Food provision (calorie supplementation as food or energy-dense supplements) compared with 










Death (at 6 months) (95% CI) 3 per 100 1 per 100 (0 ­ 4) RR 0.34  
(0.10 ­ 1.20)
567 (4 trials) Very low†‡§
Cured (at 6 months) (95% CI) 48 per 100 44 per 100  
(28 ­ 68)
RR 0.91  
(0.59 ­ 1.41)
102 (1 trial) Very low‡§¶
Treatment completion  
(at 6 months) (95% CI)
79 per 100 85 per 100  
(70 ­ 100)
Not pooled 365 (2 trials) Very low§||**
Sputum negative (at 8 weeks) 
(95% CI)
76 per 100 82 per 100  
(65 ­ 100)
RR 1.08  
(0.86 ­ 1.37)
222 (3 trials) Very low§||**
Mean weight gain (at 8 weeks) 
(95% CI)
­ ­ MD 0.78  
(–0.05 ­ 1.6)
883 (5 trials) Moderate††‡‡
Quality of life (change in quality 
of life score), mean (SD) 
At 6 weeks: 13.33 
(24.76)
14.47 (25.43) Not pooled 134 (2 trials) Low§§¶¶
At 24 weeks: 18.75 
(27.38)
8.33 (22.49)
CI = confidence interval; SD = standard deviation; RR = risk ratio; MD = mean difference; GRADE: Grading of Recommendations Assessment, Development and Evaluation.
GRADE Working Group grades of evidence:
High quality: further research is very unlikely to change our confidence in the estimate of effect.
Moderate quality: further research is likely to have an important impact on our confidence in the estimate of effect and may change the estimate.
Low quality: further research is very likely to have an important impact on our confidence in the estimate of effect and is likely to change the estimate.
Very low quality: we are very uncertain about the estimate.
*This technical summary is an adapted version of a Cochrane Review Summary of Findings table previously published[1] in the Cochrane Database of Systematic Reviews 2016, Issue 6, https://
doi.org/10.1002/14651858.CD006086.pub4 (see www.cochranelibrary.com for information). Cochrane reviews are regularly updated as new evidence emerges and in response to feedback, and 
the Cochrane Database of Systematic Reviews should be consulted for the most recent version of the review.
†Three trials reported some deaths during the 6 months of treatment (Jahnavi 2010; Jeremiah 2014; Sudarsanam 2010), and one reported that no deaths occurred (Martins 2009). The trials were 
conducted in Tanzania, Timor­Leste, and India in participants with signs of undernutrition. Martins 2009 gave a daily hot meal, Sudarsanam 2010 gave monthly ration packs, Jahnavi 2010 gave 
daily locally appropriate supplements, and Jeremiah 2014 gave high­energy multivitamin­enriched biscuits.
‡Downgraded by 1 for indirectness: trials are only available from limited settings. Food supplementation would plausibly have its biggest effect in highly food­insecure or emergency settings, 
which are not reflected in these trials.
§Downgraded by 2 for imprecision: the trials and meta­analysis are significantly underpowered to either detect or exclude an effect if it exists.
¶Data on successful cure at 6 months are only available from Sudarsanam 2010, which randomised tuberculosis patients in India to monthly ration packs or advice only.
||Two trials report on tuberculosis treatment completion at 6 months (Jahnavi 2010; Martins 2009). One trial was conducted in India and one in Timor­Leste in participants with signs of 
undernutrition. Both trials gave daily locally appropriate supplements.
**Downgraded by 1 for inconsistency. Jahnavi 2010 found a statistically significant benefit, while the larger trial, Martins 2009, did not.
††Five studies reported measures of weight gain but at different time points, which prevented meta­analysis. The relative effect was derived from three trials (Jeremiah 2014; Martins 2009 and 
Praygod 2011b) that provided change and/or actual mean weight data at 8 weeks.
‡‡Downgraded by 1 for inconsistency. Praygod 2011b included only HIV­positive patients, and although the trend was towards a benefit, this did not reach statistical significance. Jeremiah 2014 
noted a greater increase in mean weight gain in the supplemented group compared with the non­supplemented group after 8 weeks; however, the difference was not appreciable (1.09 kg, p<0.6, 
authors’ own figures). The three other trials all demonstrated clinically important benefits.
§§Downgraded by 1 for indirectness. Only two small trials, one from Singapore (Paton 2004) and one from India (Jahnavi 2010), report quality­of­life scores. The results cannot be generalised to 
other populations or settings with any certainty.
¶¶Downgraded by 1 for imprecision. The presented data appear highly skewed and could not be pooled.
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Conclusion
The review authors concluded that based on the current research 
they do not know whether routinely providing free food or 
energy supplements results in better antituberculosis treatment 
outcomes (decreased tuberculosis­related mortality, increased cure 
rate, increased tuberculosis treatment completion rate); however, 
limited evidence suggests that it probably improves weight gain 
in some settings. There is also no reliable evidence that routine 
supplementation with multi­micronutrients or specific individual 
micronutrients above recommended daily amounts has clinical 
benefits. Of note for future research, according to the review authors’ 
calculations, none of the included trials or meta­analyses of trials 
were sufficiently powered to detect clinically important effects on the 
outcomes of interest.[1]
This evidence in the South African 
context
Tuberculosis is the leading cause of underlying natural deaths in 
South Africa (SA), even through the proportions of natural deaths 
attributed to tuberculosis have declined over time (8.8% in 2013, 
8.3% in 2014, 7.2% in 2015).[7] The 2016 Global Tuberculosis Report 
estimated that SA had the sixth­greatest number of incident cases and 
third­greatest incidence in relation to population.[8] The incidence 
of multidrug­resistant (MDR) and extensively drug­resistant 
tuberculosis is increasing, and SA is deemed at risk of having a MDR 
tuberculosis­dominated tuberculosis pandemic.[9]
According to the 2015/2016 District Health Barometer,[10] the 
incidence of tuberculosis in SA has decreased over the past 5 years, 
with the most notable decline in KwaZulu­Natal Province. The 
Eastern Cape, KwaZulu­Natal and Western Cape have the highest 
incidence of tuberculosis, while Mpumalanga, Gauteng and Limpopo 
provinces rank the lowest. Districts with the highest tuberculosis 
incidence were Sarah Baartman (Eastern Cape), Pixley ka Seme 
(Northern Cape) and Nelson Mandela Bay (Eastern Cape).[10]
While the national guiding document on nutritional supple­
mentation is being finalised, most provinces implement a 
supplementation protocol based on the nutritional assessment 
and nutritional classification of individuals rather than on disease 
diagnosis or treatment status. Nutritional supplementation is 
discontinued when nutritional status goals are met. Macronutrient 
supplementation practices often depend on budget and human 
resource availability, and mostly involve providing undernourished 
individuals with varying quantities (range 2 ­ 7 kg per month) and 
combinations of enriched maize porridge, enriched energy drinks 
and mageu (lactic acid­fermented maize­based drink). Eligibility 
criteria for nutritional supplementation differ between provinces and 
according to age, mostly referring to a body mass index <18.5 kg/m2 
in adults.
Two recent studies in adult tuberculosis patients in Delft in 
the Western Cape[11] and Standerton in Mpumalanga (J Wessels, 
‘Nutritional status of patients with tuberculosis and TB/HIV 
co­infection at Standerton TB Specialised Hospital, Mpumalanga’, 
unpublished data) show that newly admitted patients with active 
tuberculosis are undernourished (body mass index <18.5 kg/m2). 
Considering the findings of these studies and the Cochrane review, 
the current national nutritional supplementation practices, which 
focus on addressing undernutrition in general rather than disease­
specific nutritional requirements, would appear to be appropriate. 
One exception may be pregnant women with active tuberculosis. In 
pregnant women, tuberculosis is associated with high mortality rates 
and poor treatment outcomes, and as such these women may require 
additional nutritional support.
In SA, the burden of tuberculosis disproportionately affects people 
who are chronically impoverished, hungry and malnourished, who 
have an increased risk not only of developing tuberculosis but also of 
poor tuberculosis treatment outcomes.[12,13] National data show that 
almost a third (28.3%) of all adults are at risk of food insecurity and just 
over a quarter of all adults (26%) are food insecure.[14] Approximately 
70% of patients (n=100) admitted to a specialist tuberculosis hospital 
in Mpumalanga were from food­insecure households (J Wessels, 
unpublished data). Patients with tuberculosis also incur substantial 
direct (e.g. transport to and from the clinic for consultation and 
treatment) and indirect (e.g. time and income loss due to absence 
from work) costs related to their condition,[15] further exacerbating the 
social inequity. Currently, only 5% of all tuberculosis patients access 
the disability grant provided through the South African Social Security 
Agency.[15] Improving access to the disability grant, as well as a possible 
expansion thereof to tuberculosis patients contingent on treatment 
adherence or other relevant improved health behaviours associated 
with tuberculosis risk (e.g. stopping smoking),[16] along with effective 
implementation of nutritional supplementation when indicated, 
deserves due attention in the fight to improve the concomitant and 
intergenerational burden of poor nutrition and tuberculosis in SA.
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